Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2008 by BeerYaakov Mental Health Center.
Recruitment status was  Recruiting
Information provided by:
BeerYaakov Mental Health Center Identifier:
First received: November 11, 2008
Last updated: November 12, 2008
Last verified: November 2008

Schizophrenia affects cognition, emotion, and behavior. Neuropsychological assessment enables a better understanding of antipsychotic effectiveness and the brain processes, underlying cognitive functioning in schizophrenia.

Neurocognitive deficits in schizophrenia patients appears to explain up to 61% of the variance of functional outcome and is an important predictor of social reintegration (Peuskens et al, 2005) and independent living activitiy (Green et al, 2004). Impaired social functioning within schizophrenia population has been associated with increased health-care costs. Since social and occupational disability may generate the largest indirect costs of the illness, treatment of cognitive deficits has an enormous impact on the cost and disability associated with schizophrenia (McGurk and Mueser, 2004).

However, the gap between cognitive science and clinical practice limits the implementation of cognitive assessment in the routine evaluation of schizophrenia patients. Pharmaceutical industry initiated numerous large scale, multisite studies on the impact of novel antipsychotics on cognitive deficits in schizophrenia patients.

The aim of this research is to develop population norms of the computerized neuropsychological assessment for effectiveness of the antipsychotic treatment in schizophrenia.


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia

Resource links provided by NLM:

Further study details as provided by BeerYaakov Mental Health Center:

Estimated Enrollment: 700
Study Start Date: July 2008
350 healthy women , aged from 18 to 89
350 healthy men, aged from 18 to 89


Ages Eligible for Study:   18 Years to 89 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

700 healthy adults (350 women and 350 men, aged from 18 to 89)


Inclusion Criteria:

  • An IQ, which is within normal range.

Exclusion Criteria:

  • Psychiatric co-morbidity.
  • Physical disability or illness.
  • A history of severe head injury.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00789906

Contact: Semyon Kertzman, MD 972-8-9776136

Beer-Yaacov MHC Recruiting
Beer Yaacov, Israel, 70350
Contact: Kertzman    972-8-9776136   
Principal Investigator: Semion Kertzman, M.D.         
Sponsors and Collaborators
BeerYaakov Mental Health Center
  More Information

No publications provided

Responsible Party: Semion Kertzman, BeerYaakov Mental Health Center Identifier: NCT00789906     History of Changes
Other Study ID Numbers: 223CTIL
Study First Received: November 11, 2008
Last Updated: November 12, 2008
Health Authority: Israel: Ministry of Health

Keywords provided by BeerYaakov Mental Health Center:
Computerized Neuropsychological Assessment
Development of Population Norms of the Computerized Neuropsychological Assessment

Additional relevant MeSH terms:
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents processed this record on November 25, 2014